论文部分内容阅读
血液病并发感染菌多以绿脓杆菌、肺炎杆菌、大肠杆菌等革蓝氏阳性菌为多,期待扩大抗菌谱和联合应用抗生素疗法。作者探讨了Moxalactam(Latamoxef,LMOX)联合妥布拉霉素(TOB)的临床效果与安全性。并发感染症(均有发热)的血液病患者88人,接受LMOX(成人4～8g/d,小儿150～300mg/Kg/d,分2～4次静脉注射或静脉滴注)和TOB(成人180～360mg/d,小儿4～9mg/Kg/d,分2～4次肌肉注射或静脉滴注)。最少治疗3天后,视病情需要继续用药。进行临床效果、细菌学和体外联用效果判断。
More blood-borne concurrent infection with Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli and other gram-positive bacteria more, looking forward to expanding antimicrobial spectrum and combined antibiotic therapy. The authors explored the clinical efficacy and safety of Moxalactam (Latamoxef, LMOX) in combination with tobramycin (TOB). 88 patients with blood diseases complicated with infectious diseases (both having fever) received LMOX (adult 4 ~ 8g / d, children 150 ~ 300mg / Kg / d in 2 ~ 4 times intravenous injection or intravenous drip) and TOB 180 ~ 360mg / d, children 4 ~ 9mg / Kg / d, divided into 2 to 4 times intramuscularly or intravenously). At least 3 days after treatment, depending on the condition needs to continue medication. Clinical effects, bacteriology and in vitro combined with the effect of judgments.